Phase 3 Study of the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in MASH
Public ClinicalTrials.gov record NCT07795164. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multinational, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Clinical Outcomes of Pemvidutide in Subjects With Noncirrhotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Phase 3, multicenter, multinational, 2-cohort, randomized, double-blind, placebo controlled, parallel-group pivotal study to evaluate the efficacy, safety, and clinical outcomes of pemvidutide treatment in subjects with noncirrhotic (F2 or F3) metabolic dysfunction-associated steatohepatitis (MASH). Participants will be assigned either to Cohort 1 based on screening histologic (liver biopsy) criteria or to Cohort 2 based on non-invasive test criteria.
Study identification
- NCT ID
- NCT07795164
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,800 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 29, 2026
- Primary completion
- Nov 30, 2028
- Completion
- Nov 30, 2032
- Last update posted
- Aug 30, 2026
2026 – 2032
United States locations
- U.S. sites
- 9
- U.S. states
- 4
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Altimmune Clinical Study Site | North Little Rock | Arkansas | 72117 | Recruiting |
| Altimmune Clinical Study Site | Fountain Valley | California | 92708 | Recruiting |
| Altimmune Clinical Study Site | Fresno | California | 93720 | Recruiting |
| Altimmune Clinical Study Site | Gardena | California | 90247 | Recruiting |
| Altimmune Clinical Study Site | Long Beach | California | 90815 | Recruiting |
| Altimmune Clinical Study Site | Miami | Florida | 33173 | Recruiting |
| Altimmune Clinical Study Site | Ocala | Florida | 34471 | Recruiting |
| Altimmune Clinical Study Site | Springboro | Ohio | 45066 | Recruiting |
| Altimmune Clinical Study Site | Westlake | Ohio | 44145 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07795164, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 30, 2026 · Synced Sep 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07795164 live on ClinicalTrials.gov.